Ardelyx (ARDX) Q2 FY26 earnings call

Ardelyx reported record Q2 FY26 revenue, driven by strong demand for Izrella and Xposa, but revised its full-year Izrella guidance downward due to unexpected payer hurdles impacting patient access. The company is implementing proactive measures to address these challenges and remains committed to its path to profitability in 2027, while also advancing its pipeline and maintaining financial strength.